Medicenna Therapeutics Corp.
http://www.medicenna.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medicenna Therapeutics Corp.
Synthekine Joins Quest To Tame IL-2 In Cancer Therapies
First clinical data from Synthekine’s IL-2 candidate and that ofrivalsMedicennawere presented at the AACR, suggesting there’s life in the modality yet.
Another Blow For Anti-TIGITs As Merck’s Vibostolimab/Keytruda Combo Misses In Phase II NSCLC Trial
Merck & Co’s combination treatment has disappointed in a challenging group of lung cancer patients, marking yet another setback for the increasingly precarious anti-TIGIT space even as some analysts say this is not the end of the road.
Harbinger Health CEO Stephen Hahn On Early Cancer Detection To ‘Move The Needle’ On Survival
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
Why Tessera Believes Its Gene Writing Platform Can Go Way Beyond CRISPR
As the first CRISPR-based therapies draw closer to approval, the Flagship-backed biotech believes its gene writing tech is the ‘definitive’ genetic medicine platform.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Medicenna Biopharma Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice